Lilly Stock - Search News

Eli Lilly Stock Falls

The Motley Fool · 18h

Has Eli Lilly Stock Peaked?

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.

Investopedia on MSN · 1d

S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens

The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's consumer price report.

MarketWatch on MSN · 9h

Eli Lilly & Co. stock underperforms Tuesday when compared to competitors

Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 and the Dow Jones Industrial Average DJIA rising 0.

Eli Lilly Gets Wall Street Backing

Hosted on MSN · 1d

Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag

Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% as three out of every four stocks in the index climbed.

Daily Journal · 1d

Stock market today: Drops for Lilly and Big Tech weigh on Wall Street, even as most stocks rise

Drops for Eli Lilly and other influential companies are weighing on U.S. indexes. The S&P 500 slipped 0.3% Tuesday, even though the majority of stocks in the index rose. The

Stocktwits on MSN · 18h

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years. The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance,

16hon MSN

As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

1d

Lilly Stock Drops 7% as 2024 Revenue Projection Falls Short of Guidance

Lilly gave hopeful income projections for 2025 ranging from $58 billion to $61 billion, therefore showing a midpoint rise of ...

12h

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

18hon MSN

5 Things to Know Before the Stock Market Opens

U.S. stock futures point higher ahead of closely watched CPI report, JPMorgan Chase stock rises on better-than-expected ...

1d

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...

18h

Eli Lilly & Co (LLY) Gets a Buy from Jefferies

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

1don MSN

Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results